<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885038</url>
  </required_header>
  <id_info>
    <org_study_id>CPP14/05</org_study_id>
    <secondary_id>DR-2015-392</secondary_id>
    <nct_id>NCT02885038</nct_id>
  </id_info>
  <brief_title>Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies</brief_title>
  <acronym>TCP</acronym>
  <official_title>Analyse de l'Effet Des caractéristiques de concentrés Plaquettaires Sur le Rendement Transfusionnel Chez Les Patients Ayant Une hémopathie Maligne et bénéficiant de Transfusions Plaquettaires à Titre Prophylactique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etablissement Français du Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Etablissement Français du Sang</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility,
      dose and source, may have an impact on transfusion responses and outcomes. Because of the
      relative scarcity of PCs the selection of a specific PC for issue to the patient remains a
      challenging process. Regulatory agencies do not fully address these characteristics in their
      recommendations for prophylactic transfusions.

      The aim of the study was to analyse the effect of product-related factors in a real life
      setting, in order to determine which ones are the most relevant when selecting PCs for
      patients in prophylactic conditions. Two different endpoints are studied: the corrected count
      increment and the platelet transfusion time intervals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected count increment</measure>
    <time_frame>24 hours post transfusion</time_frame>
    <description>Platelet increment corrected for platelet dose and body surface area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion interval</measure>
    <time_frame>7 days</time_frame>
    <description>Time interval to following platelet transfusion in days</description>
  </secondary_outcome>
  <enrollment type="Actual">1101</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphocytic Leukemia</condition>
  <condition>Hodgkin Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet concentrate transfusion</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with hematologic malignancies treated at the university hospital of Besançon
        who received at least one prophylactic platelet transfusion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatients in the hematology department between January 2001 and December 2012

          -  Hematologic malignancy

          -  At least one platelet transfusion (with platelet count ≤ 25 G/L)

          -  Age 18 and over at time of first transfusion

        Exclusion Criteria:

          -  More than one hematologic malignancy

          -  Non-malignant haematological disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BARDIAUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Etablissement Français du Sang</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

